Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 574

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 574
---
 common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheets.

|                                                                         |     | Common Stock 
 Subject to   
 Possible     
 Redemption   |             |   |
|:------------------------------------------------------------------------|:----|:-------------|------------:|:--|
| Gross proceeds from Initial Public Offering                             |     | $            |  69,000,000 |   |
| Less: Proceeds allocated to public warrants and rights                  |     |              |  (1,236,527 | ) |
| Offering costs allocated to common stock subject to possible redemption |     |              |  (4,791,126 | ) |
| Less: Redemption of common stock in connection with Trust extension     |     |              | (35,995,728 | ) |
| Plus: Accretion on common stock subject to possible redemption          |     |              |   9,449,634 |   |
| Balance, December 31, 2023                                              |     | $            |  36,426,253 |   |
| Less: Redemption of common stock in connection with Trust extension     |     |              | (17,045,763 | ) |
| Plus: Accretion on common stock subject to possible redemption          |     |              |   1,288,019 |   |
| Balance, September 30, 2024                                             |     | $            |  20,668,509 |   |

NOTE 7 — STOCKHOLDERS’ DEFICIT Preferred Stock The Company is authorized to issue 1,000,000shares of preferred stock with a par value of $ 0.0001per share. As of September 30, 2024 and December 31, 2023, there were noshares of preferred stock issued or outstanding. Common Stock Pursuant to the Charter, the Company is authorized to issue 100,000,000shares of Common Stock, $ 0.0001par value.

F-21 BELLEVUE LIFE SCIENCES ACQUISITION CORP. NOTES TO CONDENSED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (UNAUDITED) NOTE 7 — STOCKHOLDERS’ DEFICIT (cont.) As of September 30, 2024 there were 2,155,000shares of Common Stock outstanding, excluding 1,886,221shares of common stock subject to possible redemption